AZ's Gout Drug PASS-ed In Europe
This article was originally published in Scrip
Executive Summary
The European Commission has given the green light for AstraZeneca to begin marketing Zurampic (lesinurad, 200mg) in combination with a xanthine oxidase inhibitor (allopurinol or febuxostat) for the adjunctive treatment of high uric acid levels in the blood associated with gout.